コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 IH292 lung cells, middle ear cells, and A549 type II pneumocytes.
2 lls and of both IAV and IBV in primary human type II pneumocytes.
3 ecipients, and accounted for 0% to 0.553% of type II pneumocytes.
4 tion to evaluate for Y-chromosome-containing type II pneumocytes.
5 re undifferentiated, with some maturation of type II pneumocytes.
6 vasculature, bronchial epithelial cells, and type II pneumocytes.
7 EBPalpha is expressed in bronchial cells and type II pneumocytes.
8 injection, did we detect any engraftment as type II pneumocytes.
9 4b(G12D) under the control of doxycycline in type II pneumocytes.
10 ng between conidia and A549 cells, a line of type II pneumocytes.
11 A damage and is associated with apoptosis of type II pneumocytes.
12 e growth factor (KGF) is a growth factor for type II pneumocytes.
13 10% of cells) and predominantly localized in type II pneumocytes.
14 s in SCLC lines, as compared to normal human type-II pneumocytes.
16 his model incorporates human lung epithelial type II pneumocyte (A549) (upper chamber) and endothelia
18 ease of IAV in human airway cells and IBV in type II pneumocytes and as a potential target for the de
19 erentially active in cell lines derived from type II pneumocytes and Clara cells (MLE-15 and mtCC1-2
20 agious lung cancer of sheep that arises from type II pneumocytes and Clara cells of the lung epitheli
23 portant in determining the susceptibility of type II pneumocytes and interstitial cells to apoptosis.
24 ion of ENA-78 demonstrated that hyperplastic Type II pneumocytes and macrophages were the predominant
25 n more-efficient infection of human alveolar type II pneumocytes and thus more-severe lung damage.
26 ecific capacity to productively replicate in type II pneumocytes and to cope with the induced cytokin
29 erived pedigrees differentiate to type I and type II pneumocytes as well as bronchiolar secretory cel
30 MUC1 immunoreactivity was present in normal type II pneumocytes as well as in a range of atypical le
32 e that MUC1 is a powerful new marker for the type II pneumocyte cell lineage that allows us to follow
33 ronchiolar epithelial cells, macrophages and type II pneumocytes; cell types involved in adaptive imm
34 tly endocytosed and degraded by cultured pre-type II pneumocyte cells, and both processes could be bl
35 d SFTPC), which are expressed exclusively in type II pneumocytes, cells that proliferate in ventilato
38 ular endothelial cells, and primary alveolar type II pneumocytes, demonstrating a much broader tissue
39 igation-mediated PCR was performed in murine type II pneumocyte-derived MLE-15 cells infected with a
40 miRNAs in mid-gestation HFL explants during type II pneumocyte differentiation in culture, we perfor
46 sms of this protection are likely related to type II pneumocyte hyperplasia, but remain to be specifi
50 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and n
51 e EGF-receptor inactivation also resulted in type II pneumocyte immaturity, which was apparent from t
52 istochemistry studies localized MMP-1 to the Type II pneumocyte in patients with emphysema and not no
53 esized that up-regulation of p53 and WAF1 in type II pneumocytes in DAD is associated with underlying
59 ritical role of the epithelium, particularly type II pneumocytes, in the initiation and perpetuation
60 of acute lung injury, extensive apoptosis of type II pneumocytes is largely responsible for the disap
61 te cell lineage that allows us to follow the type II pneumocyte lineage during the process of lung ca
62 lineages for the peripheral lung, i.e., the type II pneumocyte lineage markers MUC1 and surfactant p
63 In chronic interstitial pneumonia, only rare type II pneumocytes (< 5%) exhibited apoptosis, and they
66 gnate ligand have long been known to promote type II pneumocyte maturation; prenatal administration o
75 e lung is altered in emphysema such that the Type II pneumocyte secretes MMP-1 and suggests that MMP-
76 induction of a proteolytic enzyme within the Type II pneumocyte suggests that the cells within the lu
78 olar lung carcinoma (BAC), a neoplasm of the Type II pneumocyte that affects humans, sheep, and small
80 ify a physical relay between AM and alveolar type-II pneumocytes that is dependent on pneumocyte Clr-
82 -S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline.
83 sette sub-family A member 3 (ABCA3) positive type II pneumocytes, was observed in the histological as
88 in the acute/proliferative phase, apoptotic type II pneumocytes were rare whereas PCNA expression wa
89 Alveolar lining cells, including type I and type II pneumocytes, were the primary infected cells.
90 nd specific proteins synthesized in alveolar type II pneumocytes, where it is assembled and stored in
91 2D, in human lung tissue, including alveolar type II pneumocytes, which express avian-type receptors.
92 rates localization of LCAD to human alveolar type II pneumocytes, which synthesize and secrete pulmon
93 examined were detected almost exclusively in type II pneumocytes, with a minor involvement of alveola